MedTrace Logo

Split-Dose R-CHOP for Older Adults With DLBCL

NCT03943901 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 may be eligible) that is often excluded from clinical trials. Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of post treatment follow-up).

Conditions

Interventions

DRUG

Rituximab

Rituximab is a monoclonal antibody

DRUG

Cyclophosphamide

Chemotherapy drug, alkylating agent

DRUG

Doxorubicin

Chemotherapy drug, anthracycline antibiotic

DRUG

Vincristine

Chemotherapy drug, plant alkaloid

DRUG

Prednisone

Steroid, anti-inflammatory

BIOLOGICAL

Pegfilgrastim

Granulocyte stimulating factor, biologic response modifier

Sponsors & Collaborators

  • Medical College of Wisconsin

    collaborator OTHER

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Christopher Fletcher, MD · University of Wisconsin, Madison

  • Nirav Shah, MD, MS · Medical College of Wisconsin Clinical Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-17
Primary Completion
2025-01-13
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03943901 on ClinicalTrials.gov